Biotech | December 24, 2025
Enveda launches Phase 1 trial for first-in-class Oral IBD therapy
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Adverse events were consistent with valbenazine’s established safety profile
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
FOP is a rare genetic disorder caused by mutations in the ALK2 kinase
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Subscribe To Our Newsletter & Stay Updated
